p16 is a major inactivation target in hepatocellular carcinoma

Cancer

Volumn 89, Issue 1, 2000, Pages 60-68

  Baek, Myung Jin ^a   Piao, Zhe ^a,c   Kim, Nam Gyun ^a   Park, Chanil ^a   Shin, Eui Cheol ^a   Park, Jeon Han ^a   Jung, Hee Jung ^b   Kim, Chul Geun ^b   Kim, Hoguen ^a  

^a Yonsei University   (South Korea)

^b Hanyang University   (South Korea)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Homozygous deletions; Methylation inactivation; p14(ARF); p15(INK4B); p16(INK4A)

Indexed keywords

PROTEIN P16;

ARTICLE; CELL CYCLE; GENE DELETION; GENE INACTIVATION; GENE LOCUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; GENE DELETION; GENES, P16; HUMANS; LIVER NEOPLASMS; METHYLATION; PROMOTER REGIONS (GENETICS); PROTEINS; RNA; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 0034235843     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3     Document Type: Article

References (41)

1. Sheu J-C. Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol 1997;12:S309-13.
2. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991;51:89-93.
3. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-90.
4. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-33.
5. Piao Z, Park C, Park J-H, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998;75:29-33.
6. Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Evidence for the presence of two tumour-suppressor genes for hepatocellular carinoma on chromosome 13q. Br J Cancer 1995;72:383-5.
7. Nishida N, Fukuda Y, Ishizaki K, Nakao K. Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol Histopathol 1997;12:1019-25.
8. Piao Z, Kim H, Jeon BK, Lee WJ, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997;80:865-72.
9. INK4 gene in liver cancer. Int J Cancer 1996;67:176-80.
10. 1NK4 in hepatocellular carcinoma. Hepatology 1996;24:575-9.
11. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu D-B, et al. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997; 25:593-7.
12. Qin L, Tang 7., Liu K, Ye S, He B, Zhang Y, et al. Alterations of CDKN2 (p16/MTS1) exon 2 in human hepatocellular carcinoma. Oncol Rep 1996;3:405-8.
13. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F, et al. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997;25:1376-81.
14. Piao Z, Park C, Lee J, Yang CH, Choi KY, Kim H. Homozygous deletion of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma. Cancer Lett 1998; 122:201-7.
15. NK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789-95.
16. Wong IHN, Lo YMD, Zhang J, Liew C-T, Ng MHL, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-3.
17. 1NK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999;116: 394-400.
18. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
19. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. Complex structure and regulation of the P16(MTS1) locus. Cancer Res 1995;55:2988-94.
20. 1NK4A transcript. Cancer Res 1995;55:2995-7.
21. ARF. Cell 1997;91:555-8.
22. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
23. Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998;58:1245-52.
24. Park J-G, Lee J-H, Kang M-S, Park K-J, Jeon Y-M, Lee H-J, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995;62:276-82.
25. Edmondson HA, Steiner PE. Primary carcinoma of liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7: 462-503.
26. Goelz SE, Hamilton SR, Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 1985;130:118-26.
27. Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH III, Busch C, Shamaa M, et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst 1995;87:1383-93.
28. Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, et al. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum Mol Genet 1995;4:1883-7.
29. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, et al. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 1995;268: 1912-4.
30. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56:150-3.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6.
32. Cairns P, PolascikTJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
33. Huang L, Goodrow TL, Zhang S-Y, Klein-Szanto AJP, Chang H, Ruggeri BA. Deletion and mutation analyses of the P16/ MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnomalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56:1137-41.
34. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer (Pred Oncol) 1996;69: 466-70.
35. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
36. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
37. El-Naggar AK, Lai S, Clayman G, Lee JJ, Luna MA, Goepfert H, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997;151:1767-74.
38. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
39. Murakami Y, Sekiya T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mut Res 1998;400:421-37.
40. INK4 in human cancer. Proc Natl Acad Sci USA 1994;91: 11045-9.
41. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 1998;58:3508-12.